Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
8 weeks today since Evgen issued their dispute over milestone payment not received and still no updates. I mean what the af is going on here? Is it too much to expect the shareholders to have an update on this, after all the $5.5m was originally said to be received by end of 2023.
I suppose the one glimmer of light is that at least Stalicla haven’t pulled the plug on the deal.
HL will take a decent sized sell which is Very unusual, might be collecting shares for buyer
Rose tinted glasses in full effect ;-)
Is this the Alice in Wonderland site ?
£40 late trade ?!?
MM's were keen to take a large dummy sell from me on Friday ?
£40K late trade ? (not £40 lol)
MM's were keen to take a large dummy sell from me on Friday ?
Hope you all had a nice Easter break. Surprised to see that anyone took up the raise offer.
Equally surprised to see inside buying, although then again, it was buttons really, so not surprised in that sense. Hardly the kind of investment sizes that inspire confidence, especially given the salaries, lack of prior inside buying etc. Rubbish deal for existing holders, naturally. Part and parcel for AIM, along with the lack of consequences for BOD failure.
Also looks like the biggest holder has come to similar conclusions to some of us. GLA.
It’s just been a disastrous 18 months since the Stalicla deal was announced. I’d like to hear from posters like xxxInvestorxxx, K3VMC, Trickymatters, Mozax for their take on things. I know we’ve not always agreed but they were all very civil and reasonable.
CJ39
“ It’s just been a disastrous 18 months since the Stalicla deal was announced. I’d like to hear from posters like xxxInvestorxxx, K3VMC, Trickymatters, Mozax for their take on things. I know we’ve not always agreed but they were all very civil and reasonable.”
Sorry, I’ve only just spotted this post.
I really like the Chronos acquisition.
“ Acquisition of Chronos Therapeutics, which features a neuropsychiatry portfolio including two assets developed to late pre-clinical stage and which sits within a resurgent area for Big Pharma, for £899,481 up front, and up to £2.5m in milestone payments, all in Evgen shares.”
Quite apart from the late stage products brought in with Chronos, they now have their neuropsychiatry experience and contacts. Since Stalicla may have decided to play hardball with EVG, they have the backup of taking sfx01 back off them and developing it through TheraCryf.
Clearly, whoever saddled them with “TheraCryf” a) thought they were being frightfully clever and b) has never been gifted a copy of “Marketing for Dummies”. Thankfully, their success will not depend on anything other than sfx001 efficacy in one or more of the many research projects going on. They are all worthy projects, but I think the gliablastoma research will get some additional prominence, due to President Biden’s interest in that field.
I added on the acquisition news, but I anticipated the subsequent slide - no stocks seem capable of sustaining any rise in this market. I added again today, so managed to get my average to 2.18p. If they have any commercial success at all, the first 3x should be an easy reach, but long term it could be stunning. If and could. Just my opinion.
I’ll be adding, gently.
I am completely with you with the name change. Chosen by a pharmacist not a businessman.
Thats the problem with companies like this. They forget that they do not exist to make tablets. They exist to make money.